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ABSTRACT
The ends of linear chromosomes are capped by
protein–DNA complexes termed telomeres. Telomere
repeat binding factors 1 and 2 (TRF1 and TRF2) bind
specifically to duplex telomeric DNA and are critical
components of functional telomeres. Consequences
of telomere dysfunction include genomic instability,
cellular apoptosis or senescence and organismal
aging. Mild oxidative stress induces increased ero-
sion and loss of telomeric DNA in human fibroblasts.
We performed binding assays to determine whether
oxidative DNA damage in telomeric DNA alters the
binding activity of TRF1 and TRF2 proteins. Here, we
report that a single 8-oxo-guanine lesion in a defined
telomeric substrate reduced the percentage of bound
TRF1 and TRF2 proteins by at least 50%, compared
withundamagedtelomericDNA.Moredramaticeffects
on TRF1 and TRF2 binding were observed with mul-
tiple 8-oxo-guanine lesions in the tandem telomeric
repeats. Binding was likewise disrupted when certain
intermediates of base excision repair were present
withinthetelomerictract,namelyabasicsitesorsingle
nucleotide gaps. These studies indicate that oxidative
DNA damage may exert deleterious effects on
telomeres by disrupting the association of telomere-
maintenance proteins TRF1 and TRF2.
INTRODUCTION
The ends of linear chromosomes are capped by protein–DNA
complexes termed telomeres. These structures protect the
chromosome ends and prevent them from being recognized
as DNA double strand breaks. Telomere dysfunction results
as a consequence of the gradual loss of telomeric DNA
that occurs during cellular proliferation in the absence
of telomerase, or upon the loss of critical telomere-
maintenance proteins (1). Cellular consequences of telomere
dysfunction include telomere end fusions and genomic instab-
ility, apoptosis or senescence [reviewed in (2)]. Increasing
evidence indicates that DNA damage may contribute directly
to the loss of telomeric DNA and function.
Numerous studies have reported increased erosion and loss
of telomeric DNA in human fibroblasts after mild oxidative
stress-induced by hyperoxia, mitochondrial dysfunction,
arsenic or UVA irradiation (3–7). In these studies the anti-
oxidant treatment prevented telomere attrition. Consistent
with this, high expression of the antioxidant enzyme, extracel-
lular superoxide dismutase, was associated with decreased
telomere erosion rates and increased cellular lifespan in
human fibroblast cell lines (8). The exact mechanism of
oxidation-induced telomere erosion is unknown. Oxidizing
and alkylating agents induce a higher density of single strand
breaks (SSBs) in telomeric DNA, compared with minisatellites
and the bulk genome (9), and provoke erosion of the 30 telo-
meric single strand tail (10). Telomeric DNA is also highly
susceptible to oxidative lesion formation in vitro (4). However,
the consequences of DNA lesions in telomeric DNA on struc-
ture and function are unknown. These studies suggest that the
telomeres are particularly sensitive to oxidative stress, and that
DNA damage in telomeres may contribute to telomere erosion.
Human telomeres consist of 5–15 kb of TTAGGG tandem
repeats and terminate in a 30 single strand tail. This tail is
proposed to loop back and invade the telomeric duplex
tract resulting in a large t-loop that protects the chromosomal
ends (11). This structure is formed and maintained by protein
complexes that associate with the telomeric end. Human
telomere repeat binding factors (TRF) 1 and 2 bind duplex
(TTAGGG)n DNA, and regulate telomere length and access of
the 30 tail (2). Defects in TRF2 induce loss of the 30 tail,
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telomere end fusions and either apoptosis or senescence even
though telomeres are not critically short (1). TRF1 acts in
telomere length homeostasis, and may have protective roles
since Trf1 deletion in mice causes embryonic lethality (12)and
telomere end fusions (13). In addition, Trf1 deficient ES cells
display decreased levels of TRF2 at the chromosome ends (13).
TRF1 and TRF2 bind to human telomeric DNA directly with
exquisite sequence specificity, and are critical for recruiting
other proteins to duplex telomeres that function in proper
telomere maintenance and capping, including TIN2, RAP1,
POT1 and Ku [reviewed in (2)]. Indeed maintenance of the
precise telomeric sequence was found to be critical for proper
function (14) and is presumably required for the association of
TRF1 andTRF2. In total, lossof theDNAorproteincomponents
of the telomeres can have severe cellular consequences.
The consequences of DNA lesions in the telomeres on
structure and function are unknown. Of the lesions induced
by oxidative stress, 8-dihydro-20-deoxyguanine (8oxoG) is one
of the most abundant. While it does not block replication by
DNA polymerase, it is highly mutagenic and could alter telo-
meric sequence (15). 8oxoG is primarily repaired through base
excision repair (BER) [reviewed in (16)]. In BER, a modified
base is removed, the DNA is incised at the abasic site, a
polymerase incorporates one or a few nucleotides at the
breaks, the displaced residues are removed and the nick is
sealed. We hypothesize that oxidative lesions and/or repair
intermediates in telomeric DNA may interfere directly with
the recognition by the TRF1 and TRF2 proteins. Here, we
observed that the presence of a single or multiple 8oxoG
lesions in defined telomeric substrates disrupted binding by
TRF1 and TRF2 proteins to varying degrees. The presence of
BER intermediates, namely a single nucleotide gap and abasic
lesions, within the telomeric tracts also inhibited TRF1 and
TRF2 interaction with the substrate. Our studies indicate that
efficient repair of DNA damage and modified bases in the
telomeres are critical for the association of telomere-
maintenance proteins.
MATERIALS AND METHODS
Proteins
Restriction enzymes and T4 polynucleotide kinase (PNK)
were from New England BioLabs. Recombinant histidine-
tagged human TRF1 and TRF2 proteins were purified using
a baculovirus/insect cell expression system as described pre-
viously (17). The baculovirus constructs for TRF2 and TRF1
were generously provided by Dr Titia de Lange (Rockefeller
University, New York, NY). The recombinant GST-tagged
TRF2DN mutant lacking the N-terminal domain was generated
by PCR using the gene encoding human TRF2 as template.
The PCR primers used were 50-TTGGATCCGAGGCAC-
GGCTGGAAGAG and 50-CGGAATTCGTTTCAGTTCA-
TGCCAAGTC (Midland Certified Reagents Co.) The
amplified fragment (encoding amino acids 45–501) was puri-
fied and cloned into the BamHI and EcoRI sites of the pGEX-
6p-2 vector (Amersham Pharmacia). The expression and
purification of the GST–TRF2DN protein, in Escherichia
coli, was as described previously (18). Recombinant human
APE1 protein was purified as described previously (19).
Substrate preparation
Oligonucleotides in Table 1 were from Midland Certified
Reagents Co. or Integrated DNA Technologies. 50 end labeling
of oligonucleotides was achieved with [g-32P]ATP (3000 Ci/
mmol) and T4 PNK. To construct substrates containing site-
specific 8oxoG (X) or tetrahydrofuran (F) lesions, the first 11
oligonucleotides (Table 1) were 50 end labeled and then
annealed to the template oligonucleotide (TPL) in a 1:2
molar ratio. To construct the nicked and one nucleotide gap
substrates, oligonucleotides NIK or GAP (Table 1), respect-
ively, were 50 end labeled and then annealed with DS to TPL in
a 1:2:2 ratio. Annealing reactions were in 50 mM LiCl,
to prevent the formation of G-quadruplex DNA, and
incubated for 95C for 5 min and then cooled to room
temperature.
DNA binding assays
Reactions (10 ml) for TRF1 and the TRF2DN mutant were
performed in TEL buffer (20 mM HEPES, pH 7.9, 150 mM
KCl, 1 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 5% gly-
cerol, 0.1% NP-40 and 5% b-casein) with substrate and protein
amounts as indicated in the figure legends. The reactions were
incubated at 4C for 20 min, followed by the addition of 2 ml of
the dye (0.25% bromophenol blue), and were loaded on a 5%
native polyacrylamide gel (37.5:1). Electrophoresis was at 4C
and 200 V for 1.5 h (TRF1) or 2.5 h (DN-TRF2) in 1· TAE
buffer. Reactions were visualized by Phorphorimager analysis
(Molecular Dynamics). The percentage bound was calculated
as described previously (20), and was corrected for back-
ground in the no enzyme control.
Binding reactions for full-length TRF2 (10 ml) were per-
formed in TRF2 binding buffer (40 mM Tris, pH 8.0, 12 mM
MgCl2, 5 mM DTT, 1 mM ATP and 100 mg/ml BSA) with
substrate and protein amounts as indicated in figure legends.
The reactions were incubated at 4C for 20 min, followed by
the addition of 5 ml 3· dye (0.25% bromophenol blue, 10%
ficoll) and were loaded on a 1% agarose gel (Seakem GTG,
BioWhittaker Molecular Applications). Electrophoresis was at
Table 1. Oligonucleotides used in substrate preparations
Sequence (50!30)
CTRL GTGGATCCGTACTTAGGGTTAGGGTTAACACGAATTCGA
8oxoG1 GTGGATCCGTACTTAGXGTTAGGGTTAACACGAATTCGA
8oxoG2 GTGGATCCGTACTTAGXXTTAGGGTTAACACGAATTCGA
8oxoG3 GTGGATCCGTACTTAXXXTTAGGGTTAACACGAATTCGA
8oxoG1-1 GTGGATCCGTACTTAGXGTTAGXGTTAACACGAATTCGA
AP-1a GTGGATCCGTACTTAFGGTTAGGGTTAACACGAATTCGA
AP-1b GTGGATCCGTACTTAGFGTTAGGGTTAACACGAATTCGA
AP-1c GTGGATCCGTACTTAGGFTTAGGGTTAACACGAATTCGA
AP-2a GTGGATCCGTACTTAGGFTTAFGGTTAACACGAATTCGA
AP-2b GTGGATCCGTACTTAFGGTTAGGFTTAACACGAATTCGA
AP-3 GTGGATCCGTACTTAFFFTTAGGGTTAACACGAATTCGA
NIK GTGGATCCGTACTTAGG
GAP GTGGATCCGTACTTAG
DS GTTAGGGTTAACACGAATTCGA
TPL TCGAATTCGTGTTAACCCTAACCCTAAGTACGGATCCAC
MXT GTGGATCCGTACGATGGTTTTAGGTGAACACGAATTCGA
MXB TCGAATTCGTGTTCACCTAAAACCATCGTACGGATCCAC
Telomeric repeats are underlined.
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4C and 100 V for 4 h in 0.5· TBE buffer. Gels were dried
onto Hybond-XL membranes (Amersham), followed by Phor-
phorimager analysis. The percentage of bound substrate was
calculated as described previously (20) for 100 and 200 nM
TRF2 (lack of detectable products at the lower TRF2
concentrations for some substrates precluded reliable quanti-
fication) (Figure 5). Values were corrected for background in
the no enzyme control, and represent the mean and standard
deviation from at least three independent experiments.
APE1 incision assay
For the incision reactions (10 ml), substrate AP-1a/TPL (1 nM)
and TRF1 (amounts indicated in the figure legend) were pre-
incubated at 4C for 20 min in TEL buffer, followed by the
addition of APE1 (28 pM). The reactions were incubated at
37C for 3 min, followed by the addition of 5 ml stop buffer
[95% (v/v) formamide, 20 mM EDTA, 0.1% (w/v)
bromophenol blue and xylene cyanol]. The reactions were
heated at 95C for 10 min and loaded on an 18% denaturing
polyacrylamide (19:1) gel. Electrophoresis was conducted at
250 V for 1.5 h in 1· TBE buffer.
RESULTS
TRF1 binding is inhibited by single or multiples
8oxoG lesions
TRF1 binds predominantly to telomeric DNA as a
homo-dimer, and each TRF1 monomer binds to a 50-
TAGGGTTR-30 minimal consensus sequence (21). To deter-
mine whether oxidative lesions interfere with TRF1 binding,
we used 39 bp DNA substrates that contained two tandem,
overlapping monomer-binding sites, in which guanine
XX XXX non-telomeric
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Figure 1. 8oxoG inhibits TRF1 binding to telomeric DNA. Boxes indicate the GGG runs of the tandem telomeric repeats, and (X) marks the position of the 8oxoG
lesion(s) within the G3 runs (see Table 1). Substrates (2.5 nM) were incubated alone () or together with decreasing concentrations of purified TRF1 (200, 100, 50 or
25 nM) (lanes 2–5, 7–10, and 12–15, 17–20, 22–25 and 27–30) for 20 min at 4C in TEL buffer. The reactions were run on 5% acrylamide native gels and
representative phosphorimager scans are shown in (A). Arrows indicate bound or free substrate. The percentage bound was determined as described in ‘Materials and
Methods’ and plotted against TRF1 concentration as shown in (B) Square, control; circle, 8oxoG1; diamond, 8oxoG2; triangle, 8oxoG1-1; and inverted triangle,
8oxoG3. Values and error bars represent the mean and SD from three independent experiments.
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residues were replaced with site-specific 8oxoG lesions
(Table 1). Electrophoresis mobility shift assays (EMSAs)
were performed with purified human recombinant TRF1 to
obtain binding curves. Migration of the telomeric substrates
was retarded as a function of TRF1 concentration (Figure 1A,
lanes 1–25), whereas the non-telomeric substrate was not shif-
ted (lanes 26–30), attesting to the specificity of TRF1 for
human telomeric DNA. The binding curve began to plateau
at 50 nM TRF1 for the undamaged control substrate
(Figure 1B), thus, all comparisons are made at 25 nM
TRF1 which falls within the linear range of the curve.
Since the central G of a telomeric tract was previously
found to be the most susceptible to oxidation in vitro (7),
this G was replaced with an 8oxoG residue. The lesion dis-
rupted TRF1 binding by 50%, relative to the control (61 – 6%
bound reduced to 31 – 6%) (Figure 1A, compare lanes 5 and
10, and Figure 1B). The presence of a single 8oxoG in each
telomere repeat (monomer-binding site) dramatically
decreased the percentage of bound substrate 18-fold to barely
detectable levels (Figure 1A, lane 15). However, when two
8oxoGs were present within a single telomere repeat, TRF1
binding was decreased only 2-fold, relative to the control, to
29 – 2% bound (Figure 1A, lane 20). Therefore, the presence
of one or two 8oxoGs in a single telomere repeat had similar
effects on TRF1 binding. In contrast, substitution of all three
tandem guanines with 8oxoGs dramatically disrupted TRF1
binding and the percentage of bound substrate was decreased
21-fold, relative to the control (Figure 1A, lane 25). In sum-
mary, a single oxidized guanine in each monomer-binding site,
or the saturation of a single site with oxidized guanines, most
strongly altered TRF1 binding.
Single nucleotide gaps disrupt TRF1
Telomeric DNA was reported to contain a higher frequency of
SSBs compared with the bulk genome after cellular treatments
with oxidative and alkylating agents (9). These breaks may
represent direct damage-induced SSBs or indirect BER inter-
mediates, including single nucleotide gaps that exist prior to
nucleotide incorporation by DNA polymerase b (22). TRF1
binding was not significantly altered by the presence of a
single strand nick within the telomeric tract (Figure 2, lanes
1–5). However, we cannot rule out the possibility that common
chemical modifications at the termini of an SSB (i.e. a 30-
phosphate or phosphoglycolate) (16) might alter TRF1
binding. The presence of a single nucleotide gap within the
telomeric tract reduced TRF1 binding 3-fold (18 – 6.4%
bound) (Figure 2, lane 10), relative to the control (61 – 6%
bound) (Figures 1A, lane 5 and Figure 1B) at 25 nM TRF1.
Thus, the loss of a single nucleotide in the telomeric tract
disrupted TRF1 binding, while a simple nick did not.
TRF1 recognition is inhibited by abasic lesions
Another important intermediate in BER is the apurinic or
apyrimidinic (AP) site. These lesions result from the removal
of a damaged base by a DNA glycosylase that initiates BER,
but also arise spontaneously 10 000 times per cell per day
(23). We tested substrates in which various guanine residues
within the telomeric tract were replaced with a tetrahydro-
furan, an AP site analog, for binding by TRF1 (Table 1).
The presence of a single AP residue decreased TRF1
(20 nM) binding 2- to 4-fold (lanes 4–12), compared with the
undamaged control (lanes 1–3), regardless of which residue
TRF1 - -
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nick
gap
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Figure 2. TRF1 binding is inhibited by a single nucleotide gap in telomeric DNA. Substrates containing either a nick or single nucleotide gap (gap) within the tandem
telomeric repeats were constructed as described in ‘Materials and Methods’. Substrates (2.5 nM) were incubated alone () or together with decreasing concentrations
of TRF1 (200, 100, 50 or 25 nM) (lanes 2–5 and 7–10) for 20 min at 4C in TEL buffer. The reactions were run on 5% acrylamide native gels and representative
phosphorimager scans are shown in (A). Arrows indicate bound or free substrate. The percentage bound was determined as described in ‘Materials and Methods’ and
plotted against TRF1 concentration as shown in (B). Square, nick and circle, single nucleotide gap.
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in the G run was replaced with an AP site (Figure 3A) (Table
2). However, the presence of a single AP residue in each
telomeric repeat inhibited TRF1 binding even more dramat-
ically (6- to 7-fold) (Figure 3B, lanes 1–9) (Table 2). When the
guanines in a single telomere repeat were saturated with AP
lesions, binding was decreased 4-fold relative to the control
(Figure 3B, lanes 10–12) (Table 2). Thus, the presence of
multiple abasic lesions within the telomeric tracts appeared
to be less disruptive to TRF1 binding than multiple 8oxoG
lesions. Nevertheless, these experiments indicate that the loss
of a single or multiple bases within a telomeric tract results in
disruption of TRF1 interactions with the substrate.
Although the presence of AP residues in telomeric DNA
decreased TRF1 binding, interaction with the DNA substrate
was not completely abolished, raising the possibility that
TRF1 could interfere with repair proteins. To test this we
examined the binding of TRF1 and APE1 simultaneously to a
telomeric substrate containing an AP residue (AP-1a, Table 1).
APE1 is the major human repair endonuclease for AP sites
(24). The majority of the substrate (1 nM) was bound by a large
excess of TRF1 (200 nM) alone (Figure 4A, lane 9). However,
the intensity of the band representing bound TRF1 decreased,
and the amount of APE1–DNA complex increased as a
function of APE1 concentration (Figure 4A, lanes 2–8). An
APE1–DNA complex was apparent even at the lowest APE1
concentration (11 nM) (lane 2), and the TRF1–DNA complex
was largely absent at near equal molar APE1 and TRF1 levels
(Figure 4A, lane 5). A super shifted complex was not detected
in any of the reactions (although some smearing was
observed), indicating that APE1 and TRF1 did not form a
stable co-complex on the substrate. Consistent with these
results, we observed that TRF1 did not interfere with the
catalytic activity of APE1. When APE1 was incubated with
the AP-1a substrate, the enzyme incised the DNA strand 50 to
the AP residue resulting in a 15 nt product (Figure 4B, lane 1).
The incision activity of APE1 was unaffected even in the
presence of up to a 7000-fold molar excess of TRF1 (Figure
4B, lane 6). Our results indicate a higher affinity of APE1 for
the AP-containing telomeric DNA, than TRF1, and suggest
that even large excess of TRF1 is unlikely to interfere with the
processing of damaged telomeric DNA by APE1.
TRF2 binding to telomeric DNA is disrupted by
oxidative and abasic DNA lesions
Although both TRF1 and TRF2 bind telomeric duplex DNA,
their roles in telomere maintenance differ. The TRF2-DNA
binding domain is 56% identical to TRF1 (25), however, the
loss of TRF2 binding to telomeres has different cellular con-
sequences, compared with TRF1 loss. Expression of a TRF2
mutant lacking the N-terminus and the C-terminal DNA
binding domain was found to induce loss of telomeric 30
tails and telomere end fusions, whereas, a similar TRF1 trun-
cated mutant did not (1,26). These proteins also differ bio-
chemically in that TRF2, but not TRF1, was observed to
promote t-loop formation of model telomeric ends in vitro
TRF1 (nM)
x x x x x x     x xxx
control    AP-1a    AP-1b   AP-1c         control    AP-2a    AP-2b       AP-3
1   2   3   4   5  6   7   8  9  10  11 12 1    2   3    4   5    6   7   8    9  10  11  12
A B
bound
free
-  20 40 -  20 40 -  20 40 -  20 40 ---- 20202020  40 40 40 40
Figure 3. Abasic sites in telomeric DNA inhibit TRF1 binding. Effects of single (A) or multiple (B) abasic sites in the telomeric DNA. Boxes indicate the GGG runs of
the tandem telomeric repeats, and (X) marks the position of the abasic lesion(s) within the G3 runs (see Table 1). Substrates (1 nM) were incubated alone (lanes 1, 4, 7
and 10) or together with increasing concentrations of TRF1 (20 or 40 nM) (lanes 2–3, 5–6, 8–9 and 11–12) for 20 min at 4C in TEL buffer. Reactions were run on 5%
acrylamide native gels. Arrows indicate the position of bound and unbound substrate.
Table 2. Relative TRF1 binding activity with AP-containing telomeric
substrates
Substrate 20 nM TRF1 40 nM TRF1
Control 1 1
AP-1a 0.45 – 0.11 0.41 – 0.24
AP-1b 0.38 – 0.12 0.41 – 0.01
AP-1c 0.24 – 0.03 0.43 – 0.08
AP-2a 0.17 – 0.00 0.27 – 0.04
AP-2b 0.14 – 0.03 0.30 – 0.06
AP-3 0.23 – 0.07 0.47 – 0.18
Values were normalized to the control and represent the mean and error from
two independent binding assays.
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(27,28). Therefore, we performed EMSA with TRF2 to deter-
mine the effects of oxidized lesions on TRF2 binding. As
observed by us and others, TRF2–DNA complexes failed to
shift into acrylamide gels (20,29). However, previous reports
indicated successful detection of TRF2–DNA complexes
migrating into agarose gels (30,31). Yet, using the reaction
buffers described in these prior reports, or those used here for
TRF1 (Figures 1–3), we detected significant binding of TRF2
to the non-telomeric substrate via the agarose gel assay, indic-
ating a lack of specificity (data not shown). This probably
resulted from the basic N-terminus of TRF2 making non-
specific contacts with the negatively charged DNA backbone.
Thus, we used a reaction buffer for which we previously
observed TRF2 complex formation specifically with a
(TTAGGG)4 containing substrate, but not with an equivalent
substrate in which the sequence was scrambled (20). We also
increased the Mg2+ concentration to further inhibit non-
specific interactions between the TRF2 N-terminus and the
DNA phosphate backbone. Under these conditions, the addi-
tion of TRF2 shifted the migration of the telomeric substrate
into the agarose gel (Figure 5A, lanes 1–5), but did not
significantly shift the non-telomeric DNA (lanes 26–30).
Following development of the binding assay, we next tested
TRF2 binding to the substrates containing site-specific 8oxoGs
or the abasic analog residue (Table 1). When a single telomeric
repeat contained either one or two tandem 8oxoGs, the per-
centage of TRF2-bound products decreased by nearly 50%,
from 37 – 8% bound to 18 – 2% and 14 – 3% bound, respect-
ively, at 100 nM TRF2 (Figure 5A, lanes 3, 8 and 18). The
presence of a single 8oxoG residue in each telomeric repeat
decreased the percentage of bound substrate to barely detect-
able levels above background (8 – 5% bound at 100 nM TRF2)
(Figure 5A, lanes 11–15). Likewise, saturation of the guanine
residues in a single telomere repeat with 8oxoGs dramatically
decreased TRF2 binding to negligible levels (Figure 5A, lanes
21–25). Overall, the data indicate that the specific binding
of full-length TRF2 to telomeric DNA is disrupted by the
presence of oxidized guanines in the telomeric tract.
Next, we tested the ability of abasic DNA to alter TRF2
binding using the substrates with defined AP sites (Table 1).
The replacement of the second or third guanine residue with an
AP residue decreased TRF2 (100 nM) binding 1.8- and 2.6-
fold, respectively, compared with the control (Figure 5B, lanes
3, 8 and 23). The presence of a single AP site in each telomeric
repeat also decreased binding 2-fold, to 17 – 4 and 15 – 1%
bound, compared with the control (37 – 8% bound) at 100 nM
TRF2 (Figure 5B, lane 3, 18 and 23). Therefore, the loss of a
single or multiple bases within a telomeric tract results in
disruption of TRF2 interactions with the substrate, similar
to TRF1.
To further confirm the 8oxoG inhibitory effect on TRF2
recognition and to obtain binding curve, we performed gel-
shift assays under similar conditions as for TRF1, but with a
TRF2 mutant that lacks the N-terminal domain (TRF2DN).
This mutant bound specifically to the telomeric control
substrate, but not to the non-telomeric substrate (Figure 6A,
lane 1–6 and Figure 6B, lanes 11–14), further supporting the
notion that the N-terminal domain is responsible for the non-
specific DNA interactions. The binding curve began to plateau
at 200 nM TRF2DN for the undamaged control substrate
(18 nM) (Figure 1C). Therefore the comparisons with the
damaged substrates are performed at 100 nM TRF2DN,
which falls within the linear portion of the curve. A single
8oxoG (G1) or multiples 8oxoGs (G2) within a single telomere
TRF1
APE1     - -
- +   +   +   +   +   +   +   +   - - - - -
1    2    3    4    5     6   7     8    9  10  11  12  13  14
substrate
product
APE1
TRF1     -
+       +     +      +     +      +
1       2       3      4        5       6   
A B
APE1
free
TRF1
Figure 4. APE1 is active on abasic site-containing telomeric substrates that are pre-bound with TRF1. (A) APE1 binding to TRF1 pre-bound telomeric DNA. The
AP-1a substrate (1 nM) (Table 1) was incubated with either TRF1 (200 nM) alone (lane 9) or together with increasing concentrations of APE1 (11, 28, 140, 700,
2800 nM, 11 mM and 28 mM) (lanes 2–8), or with APE1 alone (11, 140, 700, 2800 nM and 11 mM) (lanes 10–14) for 20 min at 4C in TEL buffer. Reactions were
initiated by the addition of APE1 and were run on 5% native gels. Arrows indicate the position of bound (TRF1 or APE1) and free substrate. (B) APE1 activity in the
presence of TRF1. The AP-1a substrate (1 nM) was incubated with either APE1 (28 pM) alone (lane 1) or with increasing concentrations of TRF1 (1, 5, 20, 80 and
200 nM) (lanes 2–6) at 37C for 3 min in TEL Buffer. Reactions were run on an 18% acrylamide denaturing gel.
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repeat decreased TRF2DN binding 5- to 3-fold to an average of
11 and 17% bound, respectively, compared with the control
(55% bound) (Figure 6). At this protein amount, the presence
of a single 8oxoG lesion in each telomeric repeat (oxoG1-1)
reduced binding to negligible levels (Figure 6B, lane 9). For
this substrate, binding was only detected at the higher
TRF2DN levels (200–400 nM), but was considerably reduced
(up to 10-fold) compared with the control (Figure 6C).
Therefore, 8oxoG is probably interfering with specific
contacts between the DNA binding domains of TRF1 and
TRF2 and the telomeric DNA. These results precisely
mimic those using the full-length TRF2 protein (see above).
DISCUSSION
In this study, we tested the effects of site-specific 8oxoG
lesions and the presence of BER intermediates within
telomeric tracts, on the binding activity of the critical
%B mean   52  37                30  18                 15   8
error       7   8                 12   2                   3  5
24 14                13  8                   5  1
2   3                  5  7                   5  1            
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X XX
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XX XXX non-telomeric
8oxoG2         8oxoG3
A
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%B mean 52 37                  42 20                    38 14
error   7   8                     9   2                    10   1        
27 17                   22 15
11   4                     2   1            
TRF2 - - - - -
X X
control           AP-1b             AP-1c
X X X X
AP-2a  AP-2b
B
bound
free
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Figure 5. 8oxoG and AP lesions disrupt TRF2 recognition of telomeric DNA. Boxes indicate the GGG runs of the tandem telomeric repeats, and (X) marks the
position of 8oxoG (A) or abasic (B) lesion(s) within the G3 runs (see Table 1). Substrates (2.5 nM) were incubated alone () or together with decreasing
concentrations of TRF2 (200, 100, 50 or 25 nM) for 20 min at 4C in TRF2 binding buffer. Reactions were run on 1% agarose gels. The arrow indicates the
unbound substrate. % Bound was determined as described in ‘Materials and Methods’. Values represent the mean and error from two to four independent experiments.
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telomere-maintenance proteins TRF1 and TRF2. We observed
that a single 8oxoG lesion resulted in at least a 50% reduction
in the amount of TRF1- or TRF2-bound substrate. When each
telomere repeat, or monomer-binding site, contained an 8oxoG
lesion, the amount of TRF1- or TRF2-bound substrate was
decreased to barely detectable levels. TRF1 binding was lar-
gely unaffected by the presence of a single strand nick within
the telomeric tract, but binding was reduced 3-fold by the
presence of a single nucleotide gap. We also tested the effect
of removing a base, rather than an entire nucleotide, using site-
specific tetrahydrofuran residues (an abasic site analog). Sim-
ilar to 8oxoG lesions, we found an AP site inhibited TRF1 and
TRF2 binding 50%, regardless of which guanine in the telo-
meric tract was replaced. These studies indicate that oxidative
stress and oxidative DNA damage in particular may exert
deleterious effects on telomeres through inhibition of TRF
telomeric protein binding.
Structural data show that the presence of an 8oxoG-C base
pair in B-form DNA imparts no gross distortion (32), suggest-
ing that the disruption of TRF1 and TRF2 binding is due to the
disruption of specific contacts required for the recognition of
telomeric sequence. TRF1 and TRF2 belong to a family of
eukaryotic TRFs that contain conserved domains which
resemble the DNA binding motif of the c-Myb transcription
activator family (25). TRF1 and TRF2 each contain a single
myb-like domain in the C-terminus and bind to telomeric DNA
as a homo-dimer [reviewed in (2)]. The solution structure of
the TRF1 myb-like domain complexed with DNA containing
the TTAGGGTTA sequence revealed specific molecular
contacts between the DNA bases and TRF1 amino acids
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Figure 6. A TRF2 mutant lacking the N-terminus binds specifically to telomeric DNA and is inhibited by 8oxoG. Effects of single (A) or multiple (B) 8oxoG lesions
within G runs of telomeric DNA. Reaction conditions and substrates were as in Figure 1. ‘mixed’ denotes non-telomeric sequence. Substrates (18 nM) were incubated
alone or together with decreasing concentrations of TRF2 (400, 200, 100 or 50 nM) for 20 min at 4C in TEL reaction buffer. The reactions were run on 5% acrylamide
native gels. Arrows indicate bound or free substrate. (C) Percentage bound was determined as described in ‘Materials and Methods’ and plotted against TRF2DN
concentration. Square, control; circle, 8oxoG1; triangle, 8oxoG2; inverted triangle, 8oxoG1-1. Values and error bars represent the mean and SD from three
independent experiments.
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(25). A helix-turn-helix (HTH) motif lies in the DNA major
groove, and amino acids in the helix contact the TAGG tandem
bases and the complementary C residues of the 2nd and 3rd Gs
in the (G)3 run (25). The stretch of Gs is essential for high-
affinity binding by a protein fragment with the TRF1 myb-
domain (21,25). Here, we report that modification of G resi-
dues in the telomeric tract disrupted binding by the full-length
TRF1 and TRF2 proteins. Conversion of any of the G bases to
an abasic site decreased binding by both full-length TRF1 and
TRF2 (Table 2) (Figures 3 and 5B), with alteration of the 3rd G
having the strongest effect. The loss of the 3rd guanine base
may alter the position of the paired C, and which may disrupt
fundamental contacts between this C and the TRF1 amino
acids. 8oxoG substitution at the central G may similarly dis-
rupt specific amino acid contacts with this G, but may also
alter interactions with its complementary C residue (Figure 1).
We have demonstrated that the loss of contacts with guanine
bases (tetrahydrofuran substitution or nucleotide loss) or the
chemical modification of guanine residues (oxidation), disrupt
TRF1 and TRF2 interactions with telomeric DNA.
In general we detected that the presence of a lesion in both
telomeric repeats inhibited TRF1 and TRF2 binding more
strongly than the presence of two lesions within a single repeat
(Figures 1, 3 and 5–6) (Table 2). Previous reports indicate that
binding via both myb-domains of a TRF1 dimer cooperatively
increases the thermal stability and affinity of the protein–DNA
complex, compared with complexes in which only one myb-
domain is engaged (21). Consistent with this, we found that
disruption of both myb-DNA binding sites more dramatically
inhibited TRF1 and TRF2 binding, compared with alteration
of a single site (Figures 1, 3 and 5–6) (Table 2). The spatial
distance between the two myb-DNA binding sites does not
alter the affinity of TRF1 homo-dimers for the substrate (21).
This is consistent with biochemical studies that support roles
for TRF1 and TRF2 in remodeling telomeric ends into com-
plex structures via mediating interaction or bridging between
different regions of the telomeric stretch (27,33). Therefore,
8oxoG or abasic DNA lesions need not occur in adjacent
telomeric repeats to influence TRF1 and TRF2 binding, and
subsequent modeling of the telomeric end into higher-order
structures. This implies, distant lesions can disrupt the higher-
order restructuring of the telomeric DNA by preventing TRF
binding. Nevertheless, evidence indicates that lesions are
formed in close proximity (within 10–20 bp) as a consequence
of ionizing radiation [(34), reviewed in (35)]. These clustered
lesions contain oxidized bases, abasic sites and SSBs on the
same and/or opposite strands.
Telomere length has been found to correlate with sensitivity
to some DNA damaging agents. Transgenic telomerase knock-
out mice with shortened telomeres, are hypersensitive to
alkylating agents (36), IR (37), doxorubicin (38) and
arsenic-induced oxidative stress (6) compared with non-
transgenic controls. Consistent with this, telomerase expres-
sion decreased the sensitivity of cultured fibroblasts with short
telomeres to IR, bleomycin, hydrogen peroxide and etoposide
by elongating the telomeres (39). Reasons for the hypersens-
itivity are unknown, but shorter telomeres have less bound
TRF1 and TRF2 (17,26). Based on our findings here, we
propose that shorter telomeres, with already lower levels of
bound TRFs, may be more sensitive to further loss of TRF
proteins upon oxidative damage. Consistent with this, the over
expression of TRF2 or telomerase, protected cultured cardi-
omyocytes from oxidative stress-induced apoptosis (40). We
found increased binding of TRF2 to the oxidized substrates at
the higher TRF2 concentrations (Figures 5 and 6).
Our findings highlight the importance of repairing DNA
damage at the telomeric end, since damage may result
in the loss of critical telomere-maintenance proteins. One
mechanism of oxidative stress-induced telomere loss has
been proposed to be blocking of the replication fork in the
telomeres by the presence of unrepaired nucleotides or bases
(4). Blocked and/or aborted replication may lead to strand
breaks and the loss of telomere repeats, and the subsequent
loss of associated TRF1 and TRF2 proteins. This is a likely
scenario for blocking lesions such as thymine glycol, but
8ooxoG does not significantly block or impede DNA poly-
merases (15). Rather, we propose that 8oxoG may interfere
with proper telomere function by directly inhibiting TRF1 and
TRF2 association, or by causing mutagenesis if unrepaired.
Loss of telomere-associated TRF2 has been found to induce
telomere dysfunction, including telomere end fusions, even in
the absence of telomere shortening (1). The binding of the TRF
proteins to the telomere repeat sequence is probably a critical
step of the maintenance process. In summary, oxidative stress
may cause the dissociation of telomeric TRF1 and TRF2 via a
combination of the loss of telomeric DNA repeats and the
inhibitory effects of DNA lesions on TRF1 and TRF2 binding.
Further studies are required to determine the direct con-
sequences of oxidative DNA lesions in the telomeric DNA
on telomere structure and function.
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